• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Statements

DNDi interventions at the 74th World Health Assembly

Geneva, Switzerland — 24 May 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi's briefing document for the 74th World Health Assembly.

DNDi's interventions:

Agenda item 13.4: Global Strategy and Plan of Action on public health, innovation, and intellectual property

The Global Strategy and Plan of Action is a roadmap of critical actions to secure innovation and access.  It is still not fully implemented. The main challenges identified have become more pronounced during COVID-19. 

 DNDi urges Member States to accelerate action. In particular:   

  • Provide funding for the WHO for the Expert Panel’s priority actions 
  • Promote and develop sustainable financing mechanisms to support R&D, which should separate the price of final products from R&D costs
  • Ensure TRIPS flexibilities are implemented in national legislation, with technical support from the WHO where needed. Support the WHO and partners work on patent databases and pooling and enact other policies for the pro-access management of intellectual property to ensure timely and equitable access
  • Support WHO, as well as regional and national regulatory agencies, to strengthen regulatory systems, including collaborative regulatory & clinical trial registration processes, to ensure timely registration of safe and effective health technologies
  • Implement recommendation 4 from the Expert Review Panel on transparency of the cost of R&D, which plays a critical role in incentivizing and projecting costs for further investment, ensuring fair pricing, and ensuring a public return on public investments in R&D. COVID-19 exemplifies the need for transparency throughout the pharmaceutical development chain to inform public investments and strategies. This need was widely cited at the recent Fair Pricing forum.
  • Support the resolution on strengthening local production of medicines and other health technologies to improve access to safe, effective and affordable health technologies. This should be a means to accelerate and focus the GSPoA recommendations on concrete deliverables on technology transfer, regulatory capacity and sustainable financing. Manufacturing needs should be mutualized across disease areas where feasible, pool demand and explore common delivery and access mechanisms.

Agenda item 17: WHO’s work in health emergencies and strengthening preparedness for health emergencies

The global response to COVID-19 is enabling major scientific advances and the development of new health technologies at unprecedented speed but is also exposing structural inequities that hinder innovation of and equitable access to life-saving health tools. The Independent Panel for Pandemic Preparedness and Response highlighted the need to transform the international COVID-19 architecture into a "truly global end-to-end platform for vaccines, diagnostics, therapeutics, and essential supplies, shifting from a model where innovation is left to the market to a model aimed at delivering global public goods."

In the short-term, urgent steps must be taken to ‘course-correct’ for COVID-19.

DNDi urges Members States to:

  • Share supply of vaccines and ensure equitable allocation to countries in need, with a focus on the populations at highest risk
  • Support the TRIPS waiver for all COVID-19 technologies
  • Support C- TAP or other IP pooling and technology transfer mechanisms and use leverage to ensure companies come to the table to share know-how and technology
  • Make investments in manufacturing capacity hubs in LMICs for vaccines and therapeutics
  • Ensure investments in treatments, diagnostics, and health systems  

In the longer term, for future pandemic preparedness mechanisms, enabling policies must be put in place to ensure the benefits of scientific progress will be equitably shared and considered global public goods, available to all.   

DNDi urges Member States to: 

  • Ensure researchers, experts, civil society, and political leaders from LMICs are equal partners in all governance mechanisms
  • Commit to and condition funding on transparency and open sharing of research knowledge, data, and costs
  • Guarantee that health tools are free of IP restrictions and develop more permanent mechanisms and rules for persistent IP obstacles, technology transfer, equitable allocation, and affordable pricing
  • Mobilise massive resources for investments in ‘pathogen-agnostic’ R&D and cross-cutting strategies that can benefit R&D efforts across disease areas

Agenda item 16: Committing to implementation of the Global Strategy for Women’s, Children’s and Adolescents’ Health 2016-2030

DNDi and Medicines for Malaria Venture (MMV) welcome progress in the implementation of the Global Strategy for Women’s, Children’s, and Adolescents’ Health. However, the need for research and development of health tools to address the needs of children and women, who are disproportionately affected by infectious disease but whose specific medical needs are often neglected, has not been sufficiently highlighted. 

Children are among the most neglected in drug development and paediatric formulations of drugs are often not developed. The needs of children with HIV illustrate this neglect where the development of optimal paediatric formulations still lags 20 years behind that of adults and whilst significant progress has been made in antimalarial development, more options are needed. Supporting research including paediatric trials and accelerating processes for developing, registering, and making available paediatric drug formulations is imperative.   

We welcome the establishment of the Global Accelerator for Paediatric Formulations Network (GAP-f), of which DNDi and MMV are members, as an important step to promote innovation of and access to quality, safe, efficacious, and affordable medicines for children.  

There is a knowledge gap in understanding the impact of medicines in females, especially for pregnant and lactating women, and women of childbearing age, who are often excluded from clinical trials due to concerns about effects on the foetus, resulting in delays in the availability of medicines. DNDi developed a proposal for a safe, ethical framework for the recruitment of women susceptible to and becoming pregnant in clinical trials and MMV have the Malaria in Mothers and Babies (MiMBa) strategy to guide their work. These and other proposals to ensure responsible strategies in gender-responsive drug development should be integrated into the strategy. 

DNDi and MMV urge Member States to ensure that innovation of −and access to− medicines for children and women is integrated into the strategy, including a requirement to report on progress. 

Agenda item 26.3: WHO reform (World NTD Day) and Agenda item 26.4: The global health sector strategies on, respectively HIV, viral hepatitis, and sexually transmitted infections, for the period 2016-2021 

DNDi welcomes the progress noted in each of the existing strategies for HIV, viral hepatitis, and sexually transmitted infections. However, significant challenges in reaching the SDG 2030 elimination goals for these diseases must be addressed as part of the new strategies.

For Hepatitis C: Most countries are still not close to meeting the existing treatment and diagnostic targets.  Not enough patients are diagnosed and, contrary to what is often claimed, access to affordable curative treatments is not a reality, particularly in high burden countries. Actions to remove barriers to scaling up diagnosis and treatments, including using TRIPS flexibilities to allow generic competition, are urgently needed.

For HIV: Only 53% of the 1.8 million children living with HIV globally were diagnosed and on treatment, and much more must be done to rapidly scale up access to optimized paediatric antiretroviral formulations as soon as they are approved; generate the evidence necessary for HIV-exposed infant prophylaxis; and explore new delivery systems for adolescents who face unique adherence challenges. A more ambitious research agenda for advanced HIV is also critically important to reduce HIV-related mortality including in relation to cryptococcal meningitis.

For STIs: The growing threat of drug resistant infections is highlighted in the report on STIs; for example decreased susceptibility or resistance to last line treatments for gonorrhea. Greater surveillance, development of new tests and treatments, and robust strategies for appropriate use and stewardship will be needed.

We urge Member States to actively engage in the development and implementation of new HCV, HIV, and STI strategies.   

DNDi also supports the resolution on World NTD day, but more is needed to reach elimination targets. In all four disease areas progress can only happen with sustained political will, appropriate health tools  to close diagnostic and treatment gaps and sustainable financing.

Agenda Item 13.5: Antimicrobial resistance

Statement on behalf of the Drugs for Neglected Diseases initiative, supported by the Global Antibiotic Research and Development Partnership (GARDP) 

We thank WHO for the comprehensive report and its support, together with funders and partners, to GARDP to develop new treatments to address drug resistance. 

The consequences of COVID-19 should encourage investment and international cooperation to prepare for and address the on-going impacts of antimicrobial resistance. The growth of drug-resistant infections is a silent pandemic. If left unchecked, humanity will be unable to treat common infections like pneumonia, infections in newborns or secondary bacterial infections in viral pandemics. Like COVID-19, drug-resistant bacteria can infect anyone, of any age, in any country. Unlike COVID-19, we can prepare now. The drug-resistant microbes are known, and meaningful change can be achieved with sufficient political will and resources.  

Currently, the response is off course. 

WHO’s latest review of antibacterial agents in development confirms that the 43 antibiotics currently in clinical development are insufficient to address drug resistance. 

Many countries lack adequate access to existing antibacterial treatments.  

Member States can take the following measures to strengthen national and global responses to drug resistance: 

  • Invest in the development of medical countermeasures for priority infections as a critical element of preparedness.   
  • Ensure that access to diagnostics, treatments, and vaccines for all is a cornerstone of preparedness and response. New and existing mechanisms should be developed and funded to accelerate and secure equitable and affordable access to treatments. 
  • Expand global cooperation across geographies and sectors, within a One Health framework. No country, organization, or sector can tackle AMR alone. 
  • Ensure low- and middle-income countries are equal partners in a comprehensive global response. 

Our collective success in fighting this pandemic will depend on governments developing a more robust, coordinated, and equitable approach. 

  

Policy advocacy Strengthening Capacities Sustainable Development Children Gender COVID-19 Antimicrobial resistance Hepatitis C Cryptococcal meningitis Paediatric HIV

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

VIEW ALL

Speak out

Please help us raise awareness by sharing this story.

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo